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1. Abstract 
Progranulin (PGRN) is a growth factor, containing 7.5 tandem repeats of a 
cysteine-rich motif, encoded by Granulin (GRN) gene. Heterozygous mutations 
of GRN are the main cause of Frontotemporal Dementia (FTD), while 
homozygous mutations lead to Neuronal Ceroid Lipofuscinoses type 11 
(NCL11), a Lysosomal Storage Disorder (LSD) showing accumulation of un-
degraded proteins and lipids (lipofuscin) inside the lysosomes. The role of GRN 
in regulating lysosomal functions is still unknown and therapies for NCLs are 
still not available or only aimed to minimize patients’ symptoms rather than to 
stop the disease progression. One of the main limit in understanding the cellular 
role of GRN is the absence of a good cellular model system, which can allow 
functional studies, as well as High Content Screening (HCS) experiments, in 
order to find drugs suitable for specific NCL11 therapies. For this reason, 
during my PhD studies I focused my work on the generation of the GRN-/- and 
GRN+/- Arpe19 cell lines by CRISPR-Cas9 technology and on a deep 
characterization of the autophagic-lysosomal phenotype in both GRN 
homozygous and heterozygous conditions. This phenotypic characterization 
allowed me to highlight differences between these two conditions. Indeed, in 
absence of PGRN, cells show an enhanced lysosomal and autophagic pathway 
with impairment of lysosomal function, in contrast to heterozygous condition in 
which there is a reduction of the autophagic flux with an unchanged number of 
lysosomes. On the other hand, I found that both in presence of half PGRN 
amount and in its absence, mTORC1 (mammalian Target Of Rapamycin 
Complex 1) activity was reduced and that the Transcription Factor EB (TFEB) 
was located into the nucleus, with a subsequent transcriptional activation of its 
autophagic-lysosomal target genes. Moreover, due to the low level of variability 
inside my cell system, I was able to quantify the lysosomal and the autophagic 
phenotype, by High Content Opera system, demonstrating that this cellular 
model is a perfect tool to perform screening of Food and Drug Administration 
(FDA) approved drugs in order to find novel therapeutic strategies for NCL11. 
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Il gene Granulin (GRN) codifica per il fattore di crescita Progranulin (PGRN) 
contenente 7.5 domini granulinici ricchi in cisteina. Mutazioni in eterozigosi in 
tale gene sono la principale causa della Frontotemporal Dementia (FTD), 
mentre mutazioni in omozigosi sono responsabili di una malattia da accumulo 
lisosomiale (Lysosomal Storage Disorder –LSD) definita Neuronal Ceroid 
Lipofuscinoses 11 (NCL11), la cui caratteristica è l’accumulo di proteine e 
lipidi non degradati (lipofuscina) nei lisosomi. Il ruolo di GRN nella 
regolazione delle funzioni lisosomiali è ancora sconosciuto e le attuali terapie 
per le NCLs sono solo finalizzate a minimizzare i sintomi nei pazienti piuttosto 
che a bloccare il progredire della malattia. Alla poca conoscenza dei ruoli svolti 
da GRN all’interno della cellula, contribuisce l’assenza di un buon sistema 
cellulare da utilizzare come modello in studi funzionali ed esperimenti di High 
Content Screening (HCS) volti alla ricerca di farmaci da utilizzare in specifiche 
terapie da applicare ai pazienti affetti da NCL11. Allo scopo di risolvere questa 
mancanza, durante gli studi del dottorato ho incentrato il mio lavoro sulla 
generazione di linee cellulari (Arpe19) recanti mutazioni nulle in omozigosi ed 
eterozigosi nel gene GRN, mediante la nuova tecnologia CRISPR-Cas9. 
L’utilizzo di questi modelli mi ha consentito una approfondita caratterizzazione 
del fenotipo lisosomiale ed autofagico in entrambe le condizioni genetiche. Tale 
caratterizzazione fenotipica ha evidenziato le differenze tra le due condizioni. 
Infatti, in assenza della proteina PGRN, le cellule mostrano un aumentato flusso 
lisosomiale ed autofagico con un danneggiamento della funzione dei lisosomi, 
al contrario, in condizioni di eterozigosi si osserva una riduzione del flusso 
autofagico mentre il numero di lisosomi resta invariato. Inoltre ho verificato che 
sia in cellule GRN-/- che in cellule GRN+/-, l’attività di mTORC1 (mammalian 
Target Of Rapamycin Complex 1) è ridotta e che il fattore di trascrizione EB 
(TFEB) è localizzato nel nucleo, con la conseguente attivazione trascrizionale 
dei geni autofagici e lisosomiali da esso regolati. Infine, grazie ai bassi livelli di 
variabilità del sistema cellulare che ho generato, ho potuto effettuare 
quantizzazioni, mediante HCS, dei fenotipi autofagici e lisosomiali, 
dimostrando così che tale sistema cellulare è un perfetto strumento per 
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effettuare screening di farmaci approvati dalla Food and Drug Administration 
(FDA) al fine di trovare nuove strategie terapeutiche per la NCL11. 
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2. Introduction 
2.1 Lysosomal Storage Diseases 
Lysosomes are cellular organelles discovered by De Duve 60 years ago1. Their 
name comes from a Greek term that means ‘digestive body’. Lysosomes play 
an important role in processes like degradation of macromolecules, homeostasis 
of the cell, regulation of autophagy, apoptosis and cell death via signal 
transduction, but also for phagocytosis and antigen presentation. All these 
processes are involved in inflammation, oncogenesis, neurodegenerative 
diseases, skin pigmentation and bone biology. Since lysosomes are crucial 
effectors of multiple cellular functions, lysosomal defects are causative of a 
group of approximately 50 inherited metabolic disorders called Lysosomal 
Storage Diseases (LSDs). 
LSDs are caused by mutations in genes that regulates lysosomal functions, like 
catabolic enzymes that are involved in degradation of macromolecules. The 
substrates of the defective enzymes build up over time, leading to excess 
cellular storage of these materials and to dysfunction in many tissues like 
nervous system, eye, bone, muscle, and reticuloendothelial system. Such 
perturbations of cellular processes ultimately lead to cell death and 
organ-specific clinical manifestations2.  
LSDs are rare disorders, with an estimated frequency of 1 in 5,000 live births3. 
Severity and age of onset in LSDs depend on different factors such as residual 
enzyme activity, location of the mutation with respect to the catalytic site, 
distribution of stored substrates, defective protein expression and other 
mechanisms that affect the life span of the cells. 
The concept of LSDs was developed in 1963 by Hers who was interested in 
glycogen storage diseases. He noticed that in Pompe disease glycogen was not 
stored in the cytoplasm but in an organelle surrounded by a membrane. For the 
first time Hers suggested that glycogen in Pompe disease was stored in 
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lysosomes4. This observation laid the ground for a new classification of the 
already clinically recognized disorders as “Lysosomal Storage Diseases”.  
Most LSDs are caused by deficiency of soluble lysosomal proteins residing in 
the lumen of the lysosome, a minority is caused by defects in lysosomal 
membrane proteins and a number of LSDs are caused by the deficiency of non-
lysosomal proteins residing in the endoplasmic reticulum, the Golgi apparatus 
and the endosomal pathway5.  
At the beginning lysosomal diseases were classified based on the storage 
compound. Clinically this classification is very useful and well accepted. 
Disorders in which the accumulation of glycosaminoglycan fragments prevails 
are classified as mucopolysaccharidoses, those dominated by lipid storage as 
lipidoses. However, in many lysosomal diseases more than one compound 
accumulates and the stored material is rather heterogeneous. This is the case of 
a number of lysosomal glycosidases, which are not specific for a certain 
substrate, but rather for a sugar residue and the stereochemistry of its linkage. 
This residue and linkage may occur in glycosaminoglycans as well as in lipids, 
so that a deficiency of the enzyme results in storage of both.  
In many other diseases there is a substantial secondary accumulation of 
compounds that cannot be explained by the specific enzymatic defect. In fact, 
some gangliosides accumulate secondarily in mucopolysaccharidoses and 
accumulation of glucosylceramide, the storage compound of Gaucher disease, 
has been detected in Niemann-Pick Type C disease. From a pathophysiological 
point of view, the storage of more than just one compound is important since 
minor storage compounds may play major roles in disease pathogenesis. Thus, 
from a biochemical point of view, the widely used classification according to 
the accumulating substrate is not fully systematic2,5. For this reason more 
recently, LSDs have been classified by molecular defects. This subset includes 
groups of disorders caused by defects in non-enzymatic lysosomal protein, 
transmembrane protein, lysosomal enzyme protection, post-translational 
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processing of lysosomal enzymes, trafﬁcking in lysosomal enzymes and 
polypeptide degradation6.  
LSDs also comprise another group of disorders named “Neuronal Ceroid 
Lipofuscinoses (NCLs)”. NCLs are grouped in LSDs because of the 
intracellular storage material, even though distinct characteristics exist. While 
in the classic LSDs, the deﬁciency or dysfunction of an enzyme or transporter 
leads to lysosomal accumulation of speciﬁc undegraded substrates or 
metabolites, accumulating material in NCLs is not a disease-speciﬁc substrate, 
but lysosomal storage can be caused by defects in secondary processes of 
membrane turnover or altered endosome and/or lysosome trafficking2,7. 
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2.2 Neuronal Ceroid Lipofuscinoses 
The NCLs, also referred to as Batten Disease, comprise a group of most 
common inherited, progressive neurodegenerative diseases of childhood8. The 
NCLs were originally classified based on the clinical onset of symptoms to four 
main forms: infantile (INCL), late-infantile (LINCL), juvenile (JNCL) and 
adult (ANCL)9. The disease clinical features range from early vision problems 
and/or seizures progressing to mental impairment, seizures of increased 
severity, progressive loss of sight and motor skills, as well as increasing 
spasticity. Children reaching the end-stages of the disease become blind, 
bedridden, spastic, and demented with poorly controlled seizures before 
expiring in their teens or early twenties10,11,12. Pathogenesis of disease leads to 
accelerated apoptosis13,14, impaired autophagy, and secondary destructive 
inﬂammation. NCLs are characterized by an accumulation of autofluorescent 
material, composed by fats and proteins (lipofuscin), in body tissues such as 
brain and retina, and speciﬁcally localized into the lysosomes15,16. Furthermore, 
NCLs show accumulation of subunit c of mitochondrial ATP synthase in 
lysosome-derived organelles although the exact biochemical mechanism of 
accumulation is unknown16.  
The NCLs are caused by defects in Ceroid-Lipofuscinoses Neuronal (CLN) 
proteins or CLN genes and, to date, 14 distinct genetic variants are recognized 
(CLN1-CLN14) (Table1).  Proteins encoded by the majority of the CLN genes 
(CLN1, CLN2, CLN3, CLN5, CLN7, CLN10, CLN12, and CLN13) are primarily 
localized to the lysosome, although some of them are known to have also 
extralysosomal functions18,19. Mutations in the CLN3 gene cause JNCL and 
encode for the CLN3 protein, which is localized to Golgi, lipid rafts, plasma 
membrane and lysosomes. CLN3 protein function is unknown and mutations in 
this gene lead to altered lysosomal pH, defective arginine transport, and 
malfunction in transport across lysosomal and vacuolar membranes20-22. 
Another common NCL variant is CLN2 disease, a LINCL, caused by a 
defective Tripeptidyl Peptidase I (TPP-1) enzyme, which removes tripeptides 
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from the N-terminal of small polypeptides23. Patients affected by lipofuscinoses 
1 present mutation in CLN1 gene and have a defective Palmitoyl Protein 
Thioesterase 1 (PPT-1) enzyme24 responsible for the cleavage of palmitate from 
S-acylated proteins25. CLN4 disease is caused by mutations in the DNAJC5 
gene, which encodes for the protein cysteine-string protein α (CSPα)26. CSPα 
plays a role as a chaperone in folding of proteins and in synaptic vesicle 
exocytosis and endocytosis27,28.  CLN10 disease is caused by mutation in the 
cathepsin D gene (CTSD, CLN10)18,29. CTSD gene in the physiological state 
codes for the protein cathepsin D, an aspartyl endopeptidase, which plays 
several roles in apoptosis. Mutation in the cathepsin F (CTSF, CLN13) gene 
leads to adult-onset NCL, also known as type B Kuf disease30. CTSF is a 
cysteine protease highly expressed in neurons and is shown to be involved in 
autophagy and proteasomal degradation18,29. Very few is known about the 
functions of proteins encoded by the genes CLN5−9, CLN11, CLN12, and 
CLN1418,29 as well as the physiological meaning of CLN proteins interactions is 
still unknown29. 
NCLs are mostly inherited in an autosomal recessive manner, but some patients 
with the adult variant of NCL show autosomal dominant inheritance11. Despite 
a worldwide distribution pattern, the incidence of NCLs varies depending on 
geographical location, ranging from 1 in 14,000 people in Iceland to 1 in 67,000 
in Italy and Germany31.  
2.2.1 Cellular and animal models of NCLs 
Model systems have always been the strategic tool to study the molecular 
mechanisms underlying human pathologies. Although very few is known about 
the pathophysiology of NCLs, the basic understanding of the disease processes 
elucidated so far, has enabled the development of cellular and animal models 
mimicking the phenotype of deﬁcient CLN genes. Most of the cellular models 
reported in literature are NCL patient lymphoblasts and ﬁbroblasts, neurons 
derived from animal models of NCL disease32−37, neuroblastoma cell line SH-
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SY5Y knock-down of the CLN genes by gene silencing based method38 and 
human induced pluripotent stem cells (iPSCs). iPSCs have gained increasing 
attention thanks to their ability of reproducing genotypic and phenotypic 
changes observed in human NCL patients. 
Table 1.  Human neuronal ceroid lipofuscinoses variants 
Disease OMIM Clinical phenotype Gene Gene product 
CLN1 256730 Classic infantile, late 
infantile, juvenile, adult 
CLN1 
(PPT1) 
PPT-1 
CLN2 204500 Classic late infantile, 
juvenile 
CLN2 
(TPP1) 
TPP-1 
CLN3 204200 Juvenile CLN3 CLN3 protein 
(battenin) 
CLN4 162350 Adult autosomal 
dominant 
CLN4 
(DNAJC5) 
DnaJ homologue 
subfamily C 
member 5 
CLN5 256731 Late infantile variant, 
juvenile, adult 
CLN5 Protein CLN5 
CLN6 601780 Late infantile variant, 
adult (Kuf, type A) 
CLN6 Protein CLN6 
CLN7 610951 Late infantile variant, 
juvenile, adult 
CLN7 
(MFSD8) 
Major facilitator 
superfamily 
domain-
containing 
protein 8 
CLN8 610003 Late infantile variant 
(epilepsy with mental 
retardation) 
CLN8 Protein CLN8 
CLN9 - Juvenile CLN9 Protein CLN9 
CLN10 610127 Congenital classic, late 
infantile, adult 
CLN10 
(CTDS) 
Cathepsin D 
CLN11 138945 Adult CLN11 
(GRN) 
Progranulin 
CLN12 - Juvenile, Kufor-Rakeb 
syndrome 
CLN12 
(ATP13A2) 
- 
CLN13 - Adult Kuf type CLN13 
(CTSF) 
Cathepsin F 
CLN14 - Infantile, progressive 
myoclonus epilepsy 3 
CLN14 
(KCTD7) 
Potassium 
channel 
tetramerization 
domain-
containing 
protein 7 
Adapted from Rakheja, D., et al. (2007) 
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However, iPSCs suﬀer, like all the models mentioned above, from high degrees 
of variation between attempts to reprogram a single ﬁbroblast line or between 
cells derived from diﬀerent patients, complicating their use in early drug 
discovery screens39. 
Mice are the most used model organism for investigating NCL pathogenesis 
and to date there are genetically engineered (CLN1/PPT1, CLN2/TPP1, CLN3, 
CLN5, CLN11 and CLN10/CTSD), and spontaneous naturally-occurring mice 
models (CLN6/nclf and CLN8/mnd) which cover all the NCLs forms40.  Mice 
models show key pathological features of their human counterparts, including 
autofluorescent cellular storage and progressive neurodegeneration41.  
Large animal models of the NCLs offer lots of significant advantages over their 
small model counterparts. Dogs and sheep models bridge the large gap in brain 
size and anatomy between rodents and human. These large animals have a 
longer life expectancy, particularly useful in investigations of long-term 
treatment effects. Furthermore, the clinical progression in larger animals is 
more comparable to that seen in human patients39 and, like the human 
phenotype, these animal models also accumulate subunit c of mitochondrial 
ATPase42. 
Using such models, a number of promising therapeutic avenues have been 
developed, such as adeno-associated viral (AAV) and lentiviral (LV)-mediated 
gene therapies, enzyme replacement therapies (ERT), stem cell therapies, and 
small molecule therapies39. 
2.2.2 Therapeutic strategies for NCLs 
Scientific research is still moving the first steps in investigating NCLs 
pathophysiology and is far from the discovery of suitable therapies. To date 
most of the experimental treatments are focused on minimising symptoms, but 
none have been able to stop the disease progression or significantly improve the 
quality of patients’ life.  
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Moreover, lysosomal diseases affecting the brain, like NCLs, present significant 
difficulties for the treatment due to the protection by blood-brain barrier 
(BBB)43. Therapies relying on the correction or replacement of the faulty 
protein require expression of the corrected protein to be sustained within the 
brain, without any associated toxicity, for long-term treatment. The historically 
trialled technique is the peripherally-administered ERT.  This therapy is based 
on the exogenous administration of the required enzyme, which should be 
internalized by cells from the extracellular space, via a specific receptor-
mediated uptake. This approach is only feasible for NCLs caused by defects in 
soluble lysosomal enzymes (CLN1, 2, 5 and 10). The first LSD successfully 
treated by ERT was the non-neuropathic Gaucher disease, although the 
neurological symptoms were not successfully healed44 because of the BBB43. 
This means that ERT is highly beneficial for the treatment of peripheral 
symptoms, but does not show clinical benefit for the Central Nervous System 
(CNS) pathologies. A strategy to avoid inaccessibility of the BBB, is to deliver 
the enzyme directly to the CNS via the ventricular space or parenchyma, but the 
long-term effect of repeated administration, the efficiency of delivery to a large 
brain area such as human one, and the effectiveness of the therapy using 
neutralising antibodies must be clarified43. 
A promising treatment option for all forms of NCLs is the viral-mediated gene 
therapy. This approach is based on the use of a LV or AAV particles containing 
a cDNA codifying the wild type protein. Viral particles are injected into the 
CNS of patients in order to express the corrected version of the protein in the 
transduced cells, thereby restoring protein function. The key advantage of gene 
therapy is the long term effect. This therapy is in fact a permanent treatment 
that does not require lifelong repeated administrations into the fragile brain, 
avoiding further damage43. Gene therapy strategies rely on a small population 
of cells receiving the normal copy of the gene. This group of cells over-
expresses and secretes the protein, which will be internalized by neighbouring 
cells45. Thus, this approach for the NCLs needs to consider whether the mutated 
protein is soluble or membrane-bound. CLN1, CLN2, CLN5 and CLN10 are 
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secreted from cells so they are compatible with such a cross-correction 
approach. For NCLs deficient in membrane-bound proteins developing a gene 
therapy is more difficult because a significantly higher proportion of cells must 
be transduced. Viral mediated therapy is currently unable to deliver protein to 
all brain regions, resulting in the need for multiple sites of therapeutic injection. 
This is due to both the size of the human brain and the high level of protection 
to external influence carried out by BBB. 
Replacement of defective protein is not the sole strategy for NCLs treatments. 
Impaired cell signalling modulation could be useful to restore the normal 
cellular function alleviating, in this way, disease pathology43. In the last years 
many small molecules, able to restore the normal enzyme activity and to 
upregulate impaired cell pathways, have been discovered. These compounds 
include immunosuppressants, pharmacological chaperons, antioxidants and 
compounds that promote the read-through of premature stop codons40. Small 
molecules therapy provides the advantage of penetrating the BBB, while 
macromolecules cannot. The BBB is distrupted in most NCLs and this allows 
therapeutic agents to reach the brain, however, once the normal function is 
restored, macromolecules become less effective39,45. Another strong advantage 
of small molecule therapy is the non-invasive methods of drug administration, 
with the possibility of generating oral formulations that represent a charming 
alternative to invasive surgical procedures. 
Another tested treatment for NCLs is the stem cell therapy. It is based on the 
principle that stem cells, derived from a healthy donor and transplanted in a 
patient, are able to migrate to the CNS, where they provide the functional 
missing protein/enzyme and differentiate into the suitable tissue type. 
Haematopoietic Stem Cell (HSC) transplantation was performed in NCL 
patients in order to normalise PPT1 activity. This therapy showed limited or no 
success because PPT1 activity was normalized in circulating peripheral 
leukocytes, but not in the cerebrospinal fluid46. Also Neural Progenitor Cells 
(NPCs) are useful for NCL therapies. NPCs are able to integrate into the host 
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CNS upon transplantation and to differentiate into neurons or glia. This type of 
treatment was tested in mice using NPCs secreting the functional protein in 
PPT1 deficient mice40. Results showed that transplanted cells were able to 
engraft, migrate throughout the brain and constantly secrete the functional 
enzyme. PPT1 secreted by the transplanted cells was shown to be internalised 
by neighbouring cells in a cross-correction protection process, associated with a 
decrease in autofluorescent storage material40. Clinical trials (ClinicalTrials.gov 
identifier NCT00337636) were carried out for NCL patients displaying a well-
advanced stage of disease. Allogenic foetal neural stem cells (HuCNS-SC) were 
transplanted into two INCL and four LINCL patients.  Post-mortem analysis 
showed evidence of donor cell engraftment and cell migration from the initial 
transplantation site but many HuCNS-SCs were not able to differentiate into 
neurons. If cells are only capable of enzyme secretion, but are not able to 
replace defective neuronal cells, therapy is only useful as neuroprotection in an 
early stage of disease and is only applicable for soluble protein NCL disease 
forms43. 
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2.3 Granulin gene 
2.3.1 Gene and protein structure 
Granulin gene (GRN) is located on chromosome 17 (17q21) of human genome 
and is composed by 13 exons47. GRN encodes for a 593 amino acids precursor 
protein, progranulin (PGRN), with a predicted molecular weight of 68.5 kDa. 
PGRN contains a signal sequence and seven and half tandem repeats 
characterized by a unique 12 cysteine motif, named granulin domain48. This 
motif consists of four pairs of cysteines flanked by two single cysteines at the 
amino and carboxyl termini (Fig.1) which generate six disulfide bonds holding 
two parallel stacked β-hairpins49,50.  
Once transcribed, PGRN undergoes maturation during which the signal peptide 
is cleaved off and the full-lenght protein is glycosylated and secreted as a 98 
kDa precursor protein. In the extracellular environment PGRN undergoes 
proteolysis mediated by proteases which cleave the linker regions between 
granulin domains releasing ~6kDa peptides, termed granulins48. Proceeding 
from the N-terminal to the C-terminal of PGRN, granulins are called: p (the half 
“paragranulin” domain), G, F, B, A, C, D, and E (Fig.1). Proteases involved in 
progranulin cleavage are: neutrophil elastase51, MMP-12 (matrix 
metalloproteinase 12, macrophage elastase)52, MMP-1453, ADAMTS-7 (a 
disintegrin and metalloproteinase with thrombospondin motifs 7)54 and 
proteinase3 (a neutrophil protease)55.   
2.3.2 Phylogenesis 
Thanks to the particular structure of the granulin motif, the identification of 
GRN homologous genes in other species was successful. No homologous genes 
were found in Fungi, whereas one GRN gene was discovered in the amoeba 
Dictyostelium discoideum, a primordial organism that dictated the divergence 
between plant and animal kingdoms. Both the sponge Oscarella carmela and 
the choanoflagellate Monosiga brevicollis have GRN gene, but, while the first 
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has most of the classical growth factor signalling, the second does not. These 
observations suggest that GRN signalling pathway evolved about 1.5 billion 
years ago before most of other pathways56.  
Many organisms, such as fish and invertebrate organisms present multiple 
copies of GRN, while in mammals there is only one member of the gene 
family56. Four GRN genes are present in zebrafish genome: two small forms 
(zPGRN-1 and zPGRN-2) containing one and half granulin motif, and two 
genes (zPGRN-A and zPGRN-B) composed by multiple granulin motifs that 
are co-orthologs of the human gene57 (Fig.2). 
 
Fig.1 Schematic representation of the GRN locus on chromosome 17, the structure of the GRN 
gene, mRNA, protein (PGRN) and consensus amino acid sequence of a granulin domain. Black 
arrows indicate cleavage sites. (Adapted from Kleinberger G., et al. 2013). 
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Fig.2 A comparison of the structure of GRN family members in humans and zebrafish. The 
circles represent the complete granulin modules of 12 cysteines, while semi-circles are partial 
granulin domains of only six cysteines. (Adapted from Bateman A. and Bennett H.P.J. 2009).  
2.3.3 GRN function 
Knowledge of GRN function is very poor, especially because of the complex 
and opposite effects of full-length protein and granulin peptides. Published 
works ascribed to PGRN multiple functions and this is emphasized by the 
different assignments used in literature: Ceroid-Lipofuscinoses Neuronal 11 
(CLN11), Granulin-Epithelin Precursor (GEP), PC cell-Derived Growth Factor 
(PCDGF), progranulin (PGRN), proepithelin (PEPI), acrogranin, epithelial 
transforming growth factor, 88kDa glycoprotein (GP88)58-62 (OMIM: 138945). 
GRN expression profile spreads through the whole body during development 
and adulthood. It is expressed particularly in epithelia, immune cells, bone 
marrow, solid organs like spleen and kidney, and CNS48,63-68. In the CNS, GRN 
is expressed in microglia and neurons reaching higher levels, in the first, upon 
activation, in the second, during maturation69. PGRN function in the brain is not 
completely clear. Recent studies suggest a neuroprotective role of PGRN 
against premature death in neurons70 and extracellular administration of PGRN 
proved an enhanced neurite outgrowth in motor and cortical neurons71. Petkau, 
T. L. et al. and Tapia, L. et al. demonstrated that depletion of GRN in mice72 
and siRNA knockdown in cultured hippocampal neurons73, lead to a reduced 
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dendritic length and to an increased number of synaptic vesicles per synapse73.  
This means that the reduction of synaptic connections is balanced by an 
enhanced transmission at single synapses level74. 
Another important role of PGRN into the brain seems to be its involvement in 
sexual differentiation. During the embryonic development, the hypothalamus 
begins a female program of differentiation followed by a masculinization step 
due to circulating androgens. GRN transcriptional levels are upregulated by 
androgens in neonatal mice and depletion of PGRN showed a reduction in mice 
masculine behaviour75,76.  
Qin J. et al in 2005 published results regarding a role of PGRN in early 
embryogenesis. PGRN is a growth factor56 and in the blastocyst it is localized 
in the trophoblast, the outside cell sheet which, after implantation, will form the 
fetal compartment of the placenta77. After implantation, PGRN continues to be 
expressed in the placenta78, in the epidermis and in the developing nervous 
system of the embryo66. This could be correlated with the still unclear role of 
PGRN in the CNS. 
PGRN is expressed in active dividing cells, as in cases of tissue remodelling 
(embryonic development) and wound healing. In adult epithelia there are high 
PGRN levels in epidermal keratinocytes and intestinal crypts65, while in 
quiescent tissue, like fibroblasts, PGRN levels are lower63. In the last one 
PGRN levels increase considerably during wound healing. In fact, when PGRN 
was added to the wounds in mouse skin, there was an increasing number of 
capillaries, neutrophils, macrophages and fibroblasts in the impaired region 
suggesting a role of PGRN in wound repair79.  
Evidence on PGRN function as a growth factor came from oncological studies 
reporting an overexpression of PGRN in cancer cells. An increase of PGRN 
levels was detected in different type of cancers, such as carcinomas60,80-82, 
gliomas83 and sarcomas84. Like the activating proliferative pathways of ERK, 
PI3K and AKT85-87, PGRN contributes to an aggressive cancer phenotype, 
making it a suitable anti-cancer treatment target. 
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Another function ascribed to GRN is the regulation of the inflammatory 
response through the balance of full-length PGRN and granulins. PGRN has a 
proliferative and anti-inflammatory activity, inhibiting tumor necrosis factor α 
(TNF-α) signalling88,89. The pro-inflammatory granulins A and E are instead 
able to induce the expression of the cytokines interleukin-8, TNF-α, and 
interleukin-1b88,90, triggering the inflammatory response which recruits, in the 
damaged site, macrophages, neutrophils, blood vessels and fibroblasts during 
wound healing process79,88,91. The balance between full-length PGRN and 
granulins is regulated by the Secretory Leukocyte Protease Inhibitor (SLPI). 
SLPI binds PGRN thus preventing the proteolytic cleavage mediated by 
neutrophil-derived proteases, such as neutrophil elastase and proteinase-356. 
2.3.4 PGRN receptors 
Knowledge of PGRN receptors is actually very poor. The first PGRN receptor 
was identified by Hu F. et al. in 201092. They found a co-localization of PGRN 
with Sortilin, a single-pass transmembrane protein localized on neurons cell 
surface. Sortilin is a member of Vps10 protein family and is located in secretory 
and endocytic compartments of eukaryotic cells93. PGRN interacts with Sortilin 
on the cell surface through a high affinity binding mediated by the last 100 
residues at the C-terminal of PGRN; a region that contains the granulin domain 
E and other C-terminal residues92. They described a process by which PGRN is 
expressed in activated microglia and, once secreted, it interacts in trans with 
Sortilin on motoneurons surface. PGRN is then internalized into the cell by 
endocytosis and directed to the lysosomes93. Through this mechanism, Sortilin 
is able to regulate extracellular PGRN levels and to maintain a correct neuronal 
function. 
One year later, in 2011, Tang W. et al. demonstrated that PGRN is able to bind 
with high affinity the TNF receptor 1 (TNFR1) and the TNF receptor 2 
(TNFR2). PGRN acts as a competitor of TNF-α on TNFRs inhibiting, in this 
way, the immune response89. This discovery supported the already known 
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PGRN anti-inflammatory function, and suggested the use of PGRN, or a 
synthetic PGRN fragment, as a therapeutic factor for diseases, like arthritis, 
characterized by a strong immune response89. 
2.3.5 GRN related diseases 
In classical recessive disorders, heterozygous individuals are healthy carriers 
that do not show mutation-related symptoms. Classical dominant disorders are 
characterized by individuals that show the phenotype when the mutation occurs 
in heterozygous; usually homozygous are rare and the phenotype is a severe 
form of the heterozygous one. GRN mutations cause different 
clinicopathological phenotypes in heterozygous and homozygous forms94. GRN 
heterozygous null mutations are causative of Frontotemporal Dementia 
(FTD)95, while homozygous mutations that produce a complete abolition of 
PGRN give rise to NCL1194.  
FTD is the second most common form of presenile dementia after Alzheimer 
disease. It represents 5-15% of all dementia and usually appears in people under 
60 years of age96,97. FTD is an inherited autosomal dominant disease with 
incomplete penetrance98,99. It is characterized by neuronal atrophy of the frontal 
and anterior temporal lobes, which are involved in regulating behaviour, 
language and empathy. In fact the most evident symptoms are social 
withdrawal, apathy and behavioural changes100. Depletion of one GRN allele 
induce the formation, in neurons, of cytoplasmic and nuclear inclusions 
containing ubiquitinated and phosphorylated fragments of TAR DNA-binding 
protein 43 (TDP-43)101,102. TDP43 is an RNA-binding protein and splicing 
modulator that also binds GRN mRNA103,104. Loss of 50% of expressed or 
secreted PGRN is due to nonsense mutations or frameshift mutations that 
generate a Premature Termination Codon (PTC), with subsequent degradation 
of the transcript by the Nonsense-Mediated mRNA Decay (NMD)105. Other 
mutations can affect the signal peptide impairing PGRN secretion, or can 
modify a splicing donor thus leading to nuclear intron retention and transcript 
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degradation106, as well as carry out the deletion of the whole copy of the GRN 
gene107,108.  
NCL11 is an inherited autosomal recessive disorder caused by homozygous null 
mutations in GRN gene94. As other NCLs, it is characterized by accumulation of 
lipofuscin, an aggregate of oxidized cross-linked proteins and lipids, into the 
lysosomes109. Smith et al. in 2012 described two cases of adult-onset NCL11 
affecting siblings of Italian origins. The proband, a 28-year-old male, displayed 
progressive visual failure at 22 years followed by convulsions at 25 years and 
seizures at 26 years. He presented cerebellar ataxia, cerebellar atrophy, early 
cognitive deterioration and retinal dystrophy with optic nerve atrophy, vessel 
attenuation and irregular retinal pigmentation94,110. The proband’s 26-year-old 
sister started having convulsions at 23 years and her vision began to deteriorate 
at 25 years old. She displayed cerebellar ataxia, cerebellar atrophy and retinal 
dystrophy94,110. Genetic analysis revealed a 4bp deletion in the GRN gene of the 
two siblings. The c.813_816delCATC (rs63749877) mutation generates a 
frameshift followed by a PTC94. The absence of PGRN was confirmed by 
analysis of circulating fluids and peripheral tissues. Skin biopsy revealed 
cytoplasmic vacuoles, empty or containing electrondense structures, and 
polymorphic lysosomal storage in glandular and endothelial cells94,110.  
Storage of abnormal autofluorescent lipopigments (lipofuscin) was impossible 
to check in human GRN-/- brain since patients are alive, but it was observed in 
the neurons of Grn-/- mice, which reproduce the NCL11 human pathology111. To 
date, five different mouse models of NCL11 (Grn-/-) exist and all of them, 
which have different genetic backgrounds, show an accelerated accumulation of 
the aging pigment lipofuscin in the brains72,112,113 suggesting a more rapid aging 
in neurons115, associated with vacuolation in the habenula and hippocampus114. 
Lipofuscin accumulation occurs normally during aging and it is accounted as a 
cellular aging marker in post-mitotic cells like neurons. Its formation is due to 
mitochondrial repair mechanism defects, oxidative stress and dysfunction in the 
proteasomal and/or autophagic-lysosomal degradation systems113,114. These 
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observations support the already known PGRN function in neuronal survival70 
and a possible involvement of PGRN in the autophagic-lysosomal pathway. 
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2.4 Transcription Factor EB: the master regulator of 
autophagy and lysosomal biogenesis 
Autophagy is a catabolic process by which the cytosolic material, including 
proteins, lipids and organelles, is directed to the lysosome and degraded115-117. 
Autophagy has an important role in regulating cellular quality control in 
neurons since the accumulating material cannot be reduced by cellular 
divisions118, therefore autophagy impairment leads to neurodegenerative 
disease118-120. 
There are three types of autophagy: chaperone-mediated autophagy, 
microautophagy and macroautophagy. The Chaperone-mediated autophagy is 
based on the direct transport of the cytosolic proteins into the lysosome, in this 
case the proteins must be unfolded by chaperones. Microautophagy relies on the 
invagination of lysosomal membrane with subsequent import of a small amount 
of cytoplasmic material into the lysosome. Macroautophagy (referred to as 
autophagy) is the most studied and needs a double membrane organelle, the 
autophagosome, in order to deliver material to the lysosome121 (Fig.3).  
The autophagic process begins with the formation of a small vesicular sack 
called phagophore or isolation membrane. The phagophore elongates and 
incorporates a portion of cytoplasm leading to the formation of a double 
membrane structure called autophagosome. Afterwards, the outer membrane of 
the autophagosome fuses with the lysosome leading to the generation of the 
autolysosome. Inside the autolysosome all the material and the inner 
autophagosome membrane are degraded producing amino acids and other small 
molecules that will be delivered back to the cytosol for recycling or used to 
produce energy121 (Fig.3).  
Autophagosomes and lysosomes are the main actors of the so called “cell 
clearance process” by which the accumulated material is degraded and recycled. 
Settembre C. et al. demonstrated that biogenesis of autophagosomes and 
lysosomes is co-regulated by the transcription factor EB (TFEB)122.  
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Fig.3 Image representing the three main autophagic processes: chaperon-mediated autophagy, 
microautophagy and macroautophagy. (Adapted from Kaur J. and Debnath J. 2015). 
 
  
TFEB is a member of the microphthalmia-transcription factor E (MiT/TFE) 
subfamily of basic helix-loop-helix leucine zipper (bHLH-Zip) transcription 
factors123. It recognizes and binds a 10-base E-box-like palindromic sequence, 
the GTCACGTGAC motif, located within 200bp from the transcription start 
site and named Coordinated Lysosomal Expression and Regulation (CLEAR) 
element124. TFEB regulates the expression of genes related to lysosomal 
biogenesis and function124 and activates the transcription of autophagic genes, 
all of which contain the CLEAR motif in their promoter122. 
TFEB activity is regulated by post-translational modifications. In basal 
conditions, under nutrient-rich conditions, TFEB is located into the cytoplasm 
with a particular enrichment on lysosomes. In starved condition (absence of 
nutrients) TFEB is located into the nucleus122,124. TFEB activation and 
localization depend on the activity of mammalian Target Of Rapamycin 
(mTOR), which is a kinase that localizes to the cytoplasmic surface of 
lysosomes as part of the mTOR Complex1 (mTORC1), and on the activity of 
Extracellular signal-Regulated Kinase 2 (ERK2), which belongs to the MAPK 
pathway122,125-127. mTORC1 is responsible for the phosphorylation of TFEB on 
Ser211126,127, while ERK2 is responsible for the phosphorylation of Ser142122. 
In basal condition mTORC1 is active, localizes on lysosomal membrane, and 
phosphorylates TFEB recruiting it on lysosomes. Once phosphorylated, TFEB 
is in its inactive form, interacts with 14∙3∙3 protein and localizes into the 
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cytoplasm. In absence of nutrients, or in cases of lysosomal dysfunctions, 
mTORC1 is released from the lysosomal membrane and becomes inactive. 
TFEB, in its unphosphorylated and active form, moves to the nucleus where it 
activates the transcription of its target genes126,127 (Fig.4). 
As previously reported, LSDs are characterized by an accumulation of 
undegraded material in the lysosomal lumen due to genetic defects in specific 
lysosomal proteins128,129. LSDs mouse models show a significant nuclear 
localization of TFEB, indicating that the cellular response to the accumulation 
of undegraded material inside the lysosomes is based on the enhancement of 
lysosomal biogenesis124. In different publications it was demonstrated how the 
overexpression of TFEB, and so the induction of the autophagic-lysosomal 
pathway, in cellular and animal models of LSD, could ameliorate the phenotype 
leading to a reduction of the accumulated undegraded substrates in cells and 
tissues130-133. Therefore TFEB could be a suitable target of therapeutic strategies 
for LSDs and neurodegenerative disorders.  
 
Fig.4 Representation of TFEB regulatory mechanism mediated by mTORC1. (A) Nutrient rich 
condition: active mTORC1 localizes to lysosomes and phosphorilates TFEB, which in turn 
interacts with the 14∙3∙3 protein and is retained into the cytosol. (B) Starvation: inactive 
mTORC1 is released from lysosomes and dephosphorylated TFEB migrates into the nucleus 
where it activates the autophagic and lysosomal target genes.  
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2.5 CRISPR-Cas9 system 
Identification of gene function has always been the first step to develop 
successful therapies for genetic diseases. Reverse genetic and therefore, the 
generation of KO model systems, is actually the most powerful approach to 
unravel gene function.  
In the recent years the most used genome editing technologies are based on the 
use of Zinc Finger Nucleases (ZFNs) and Transcription Activator-Like Effector 
Nucleases (TALENs). These are artificial fusion proteins composed by a DNA 
binding domain fused to a non specific nuclease domain which produces double 
strand breaks in a target genomic locus, with subsequent generation of 
mutations. In the last three years a new genome editing technology emerged: 
the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 
nuclease system. 
CRISPR-Cas9 system is one of the protective systems that bacteria and archaea 
evolved as a defence mechanism against virus infections134. This adaptive 
immunity system is based on the ability of the CRISPR array to integrate 
fragments of exogenous DNA (spacers or protospacers), resulting in a 
sequence-specific resistance to the corresponding virus135. CRISPR-Cas 
mediated immunity occurs in three steps. The first one is the “acquisition 
stage”, that is the integration of a new spacer into the CRISPR locus. The 
second step is the “expression stage” where the CRISPR array is transcribed 
and the precursor transcript is processed into smaller CRISPR RNAs (crRNAs). 
The last step is the “interference stage” characterized by the formation of Cas-
crRNA complex which recognises and cleaves the invading DNA136 (Fig.5).  
Three different types of CRISPR-Cas systems exist. Type I systems are based 
on the Cas3 nuclease-helicase activity; type II systems are characterized by the 
activity of the Cas9 nuclease; type III systems are the less characterized, they 
involve the Cas10 which is a large protein whose function is unknown136,137. 
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Type I and III CRSPR-Cas systems are present in archaea and bacteria while 
the CRISPR-Cas type II system is specific for bacteria. 
CRISPR-Cas type II system from Streptococcus pyogenes is the well-known 
and best characterized. Type II system incorporates fragments of the invading 
DNA between the repeat sequences of the CRISPR array, the transcribed array 
is processed into crRNAs, which contain the protospacer sequence and part of 
the CRISPR repeat, then each crRNA hybridizes with a transactivating CRISPR 
RNA (tracrRNA)138. The crRNA-tracrRNA hybrid interacts with the Cas9 
nuclease and drives it on the target DNA. The protospacer of the crRNA 
recognises the complementary sequence on the target DNA flanked by the 
Protospacer Adjacent Motif (PAM) and here the Cas9 generates a double-strand 
break followed by the degradation of the exogenous DNA139,140 (Fig.6A). 
 
Fig.5 Adaptive immunity CRISPR–Cas system: acquisition (yellow), crRNA processing (pink), 
crRNA assembly and surveillance (blue) and target degradation (purple). The acquisition stage 
is characterized by the entry and fragmentation of the invading DNA, so that a new protospacer 
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(green) is integrated into the CRISPR array. During the expression stage the CRISPR locus is 
transcribed and the pre-crRNA is processed, by CRISPR-associated (Cas6) and/or 
housekeeping ribonucleases (such as RNase III), into small crRNAs. The Cas proteins and 
mature crRNAs are assembled into a crRNP complex in the interference stage, during which the 
crRNA recognizes the target DNA and induces the Cas mediated cleavage, followed by the 
target degradation. (John van der Oost, et al. 2014). 
This type II system of S. pyogenes has been adapted to achieve genome editing 
in cellular and animal models. The crRNA and the tracrRNA were fused to 
generate a chimeric single-guide RNA (gRNA)141 containing, at the 5’, 20 
nucleotides (corresponding to the protospacer crRNA sequence) which 
recognise the target DNA sequence followed by the PAM 5’-NGG 
sequence142,143 (Fig. 6B and 7). Once introduced, or expressed, the Cas9 and the 
gRNA into the model system, the gRNA interacts by Watson and Crick base 
pairing with the target site driving the Cas9 at the desired locus. The Cas9 
introduces, ~3 bp upstream the PAM sequence, a double strand break (DSB) 
which typically undergoes one of two major pathways for DNA damage repair: 
the error-prone Non-Homologous End Joining (NHEJ) or the high-fidelity 
Homology Directed Repair (HDR) pathway142,144 (Fig.8). In the NHEJ pathway 
the ends of the DSB are re-joined with insertions or deletions of some 
nucleotides (INDEL mutations) which, in the coding sequence, can result in 
frameshifts and subsequent generation of PTCs leading to gene KO. The HDR 
pathway can be used to introduce specific mutations. This mechanism needs a 
DNA repair template (called “donor DNA”) in form of plasmid or single-
stranded DNA oligonucleotides (ssODNs). HDR pathway is triggered less 
frequently than NHEJ and occurs only in dividing cells. Moreover, HDR 
efficiency depends on several factors such as the genomic locus, the repair 
template and the cell type and state144. 
CRISPR-Cas9 technology is the most powerful system for genome editing and 
offers the possibility to target different genomic loci simultaneously. In fact, the 
Cas9 can be re-targeted to a new genomic site only changing the 20nt gRNA 
sequence and Cas9 domains (HNH and RuvC) can be mutated in order to 
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generate different forms of Cas9 nucleases, therefore expanding the range of 
CRISPR-Cas9 technology applications145.  
 
Fig.6 Naturally occurring and engineered CRISPR-Cas systems. (A) CRISPR system type II of 
S.pyogenes: the exogenous DNA is integrated into the CRISPR array; the crRNAs, containing 
the protospacer region, hybridize to tracrRNAs encoded by the CRISPR system; the crRNA-
tracrRNA hybrid associates with the Cas9 forming a complex that recognizes and cleaves the 
invading DNA bearing the protospacer sequence. (B) The engineered CRISPR-Cas9 system is 
based on the fusion of crRNA and a portion of tra-crRNA sequences. This single gRNA forms a 
complex with the Cas9 that induces the cleavage of the target DNA sequence complementary to 
the 5’ 20 nucleotides of the gRNA. (Sander J.D., et al. 2014) 
 
Fig.7 SpCas9 interacting with gRNA. Cas9 nuclease from S. pyogenes (yellow) is recruited on 
the target site by a gRNA consisting of a 20-nt guide sequence (blue) and a scaffold (red). The 
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guide sequence pairs with the DNA target (blue bar on top strand), directly upstream the 5′-
NGG adjacent motif (PAM; pink). Cas9 mediates a DSB ~3 bp upstream the PAM sequence 
(red triangle). (Ran F.A., et al. 2013) 
 
Fig.8 DNA damage repair mechanisms: Non-Homologous End Joining (NHEJ) and Homology 
Directed Repair (HDR). The NHEJ pathway induces the insertion or deletion of nucleotides 
(INDEL mutations) which can lead to frameshifts and generation of a PTC. The HDR pathway 
allows a precise genome editing in presence of a DNA template carrying single nucleotide 
substitution or a specific sequence that must be inserted into the genomic target site. (Ran F.A., 
et al. 2013) 
To date, different Cas9 mutants have been generated. Cas9 RuvC1 catalytic 
domain was mutated with an aspartate-to-alanine substitution (D10A) to 
produce a Cas9 nickase mutant (Cas9n). Cas9n generates single strand DNA 
cleavages, instead of DSB, in the target sites, therefore promoting the HDR 
rather than the NHEJ DNA repair mechanism144. A double Cas9 mutant, which 
contains two mutations into the RuvC1 and HNH nuclease domains (D10A and 
H841A), was generated and it was demonstrated that this “dead” Cas9, which 
lost its cleavage activity, can be used to knock down gene expression in 
mammalian cells146. 
Despite the CRISPR-Cas9 system offers lots of advantages with respect to other 
genome editing tools, the main problem of this approach is the off-targets 
cleavage. Lots of bioinformatic programs, which allow the recognition of off-
target sites by gRNAs, raised up recently and many studies were conducted to 
overcome this limit. Since it was demonstrated that the CRISPR-Cas9 is 
sensitive to mismatches close to the PAM sequence, as two or more mismatches 
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in this region completely abolished the CRISPR-Cas9 nuclease activity145,147,148, 
a possible strategy to avoid off-target cleavages involves the design of gRNAs 
that present three or more mismatches at the 3’ of the gRNA sequence149. A 
different strategy, aimed to reduce the off-targets cleavage, was developed in 
2016 by Slaymaker I.M. et al. They generated some Cas9 mutants carrying 
alanine substitutions in the groove between the HNH, RuvC and PAM 
interacting domains. This positively charged groove interacts and stabilizes the 
non-target DNA strand of the target DNA. Abolition of positive charges 
enhances the rehybridization between the target and non target DNA strands, so 
a more stringent Watson and Crick base pairing is necessary between the target 
DNA strand and the gRNA150. 
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3. Aim of the work 
Because of the storage of lipofuscin inside to the lysosomes, NCL11 is a 
genetic disease classified as LSD. The molecular mechanisms leading to the 
pathogenesis of NCL11 is still poorly understood and very few is known about 
the function of GRN, the gene that, if mutated, is causative of this disease. The 
absence of a good therapy for NCL11 patients is a consequence of this lack of 
knowledge. Indeed, available therapies for the treatment of these patients are 
only aimed to ameliorate their pathological status without stopping the 
degeneration associated with the disease. The goal of this project was to 
generate a good cellular model system with low degree of variability and, 
therefore, suitable for cell biology and HCS experiments that actually are not 
feasible with the available tools. By the use of this cellular model, I performed 
experiments aimed to unravel the cellular role of GRN within lysosomes and to 
find new suitable therapies for the treatment of NCL11 patients. For the 
generation of this cellular model I took advantage of the CRISPR-Cas9 
technology in order to knock out the GNR gene in Arpe19 (retinal pigmented 
epithelium) cells. GRN edited cell lines were characterized in order to define the 
NCL11 phenotype. The autophagic-lysosomal pathway was investigated in 
GRN KO cells in order to highlight the impaired mechanisms that are 
responsible for lipofuscin accumulation. The underlined phenotype was then 
analysed by OPERA system, through a specific script, in order to quantify the 
lysosomal defects in GRN KO cells. All these results will be used to perform a 
High Content Drugs Screening aimed to find new suitable therapies for the 
treatment of NCL11 affected patients. 
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4. Materials and Methods 
4.1 Cell culture, transfections and plasmids 
Arpe19 were purchased from ATCC and cultured in DMEM-F12 (Invitrogen) 
supplemented with 10% FBS, 1% penicillin/streptomycin and 2mM L-
Glutamine (Euroclone). Cells were grown at 5% CO2 at 37°C. Starvation 
treatments were performed in HBSS-10mM Hepes. Cells were rinsed twice 
with starvation medium, then kept in a full volume of starvation medium for 1h. 
Bafilomycin A1 (100nM) (Sigma Aldrich) was added in the culture medium 
and cells were treated for 1h.  
Plasmids preparation was performed with CompactPrep Plasmid Maxi Kit 
(QIAGEN). Arpe19 cells were transfected with Amaxa® Cell Line 
Nucleofector® Kit V for all-in-one vector (pGS-CMV-Cas9/PURO, 
GeneCopoeia) containing the gRNA sequence and with Lipofectamine 2000 
(Invitrogen) for LC3-RFP–GFP plasmid (from T. Yoshimori) following the 
manufacturer’s protocol. 
4.2 Generation of GRN+/- and GRN-/- clones 
To obtain GRN+/- and GRN-/- Arpe19 clones, 1x106 cells were nucleofected with 
the all-in-one vector (pGS-CMV-Cas9/PURO, GeneCopoeia) containing the 
gRNA sequence. 24h after nucleofection, 0.2 μg/ml puromycin was added to 
cell culture for one week. The transfected cell pool was plated into 96-well 
plate by single cell sorting using DB FACSAria. Sorted cells were kept in 
culture until confluence, then the 96-well plate was duplicated, one aimed to 
cell growth and the other one aimed to DNA extraction. For genomic DNA 
extraction cell clones were washed twice with PBS and 60ul of DirectPCR 
Lysis Reagent (Viagen) was added to the plate following the manufacturer’s 
protocol. 2ul of genomic DNA preparation was used to perform the PCR in 
order to amplify the genomic locus of interest. AmpliTaq Gold® 360 Master 
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Mix (Thermo Fisher Scientific) and two primers (Forward: 5’-
CACCAGCTCCTTGTGTGATG-3’ and reverse: 5’-
CTGTTAGTCCTCTGGGCAGG-3’) were used for PCR amplification 
following the manufacturer’s protocol. PCR products were subjected to Sanger 
sequencing in order to identify INDEL mutations. 
4.3 Western blotting 
1,5x105 cells were plated in 6-well plates. 48h after plating, cells were washed 
twice with PBS and then scraped in RIPA lysis buffer (20 mM Tris pH 8.0, 150 
mM NaCl, 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate) in the presence 
of PhosSTOP tablets (Roche) and Protease Inhibitor Cocktail (Sigma). Cell 
lysates were incubated on a shaker for 30 min at 4°C. Samples were then put 3 
min in dry-ice and 3 min in a 37°C water bath (repeated for three times). The 
soluble fraction was isolated by centrifugation at 13,000 r.p.m. for 20 min at 4 
°C. Protein concentration was measured by using colorimetric Bradford method 
(Bio-rad). Samples were mixed with Laemmli buffer containing β-
mercaptoethanol, boiled 80°C for 10 min and resolved by SDS-PAGE. 
Electrophoresis was run at 100V constant in MOPS buffer (2.5mM MOPS, 
2.5mM Tris Base, 0.1% SDS, 1mM EDTA, pH 7.7). Proteins were blotted onto 
polyvinylidene fluoride (PVDF) membranes and blocked for 1 hour with non-
fat 5% milk diluted in PBS-0,1%Tween 20 (PBS-T). Membranes were probed 
with primary antibodies, diluted with BSA 5% in PBS-T, overnight at 4°C. The 
next day membranes were washed twice in PBS-T and incubated with 
corresponding HRP-labelled secondary antibodies (Calbiochem) in 2.5% milk 
in PBS-T. After three washes in PBS-T, protein visualisation was performed 
using the Super Signal West Dura substrate (Thermo Scientific). The western 
blotting images were acquired using the Chemidoc-lt imaging system (UVP) 
and band intensity was calculated using ImageJ software using the ‘Gels and 
Plot lanes’ plug-in. Antibodies used for western blotting are: β-actin (Sigma, 
cat. A5316, 1:10000), PCDGF (PGRN) (Invitrogen, cat. 40-3400, 1:500), 
LAMP-1 (Santa Cruz, cat. sc-20011, 1:1000), LC3 (Novus, cat. NB100-2220, 
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1:2000), TFEB (Cell Signalling, cat. 4240, 1:1000), 4EBP1 (Cell Signalling, 
cat. 9644, 1:1000), phospho-4EBP1 (Ser65) (Cell Signalling, cat. 9456, 
1:1000). 
4.4 Quantitative real-time PCR 
Wt, GRN+/- and GRN-/- Arpe19 cells were plated into 6-well plates (1.5x105 
cells/well). RNA extraction was performed after 48h by RNeasy Mini Kit 
(Qiagen). 500ng of each RNA sample was reverse transcribed to single-
stranded cDNA by using QuantiTect Rev Transcription Kit (Qiagen) in a final 
reaction volume of 20μl. cDNA mixes were diluted 1:6 in water, and 3μl of the 
diluted cDNA solution was analysed by Real-Time PCR. Real-time PCR was 
performed using LightCycler® 480 SYBR Green I Master (Roche) and 
performing the reaction in the LightCycler® 96 System (Roche). The 
parameters of Real-time PCR amplification were defined according to Roche 
recommendations. To quantify gene expression, beta-2-microglobulin (B2M) 
mRNA expression was used as an internal reference. Primers used in this work:  
B2M forward: GCTCGCGCTACTCTCTCTTT 
B2M reverse: CAATGTCGGATGGATGAAACCC 
GRN forward: CCAGATGCCTGCTCAGTGT 
GRN reverse: AGATGGTCAGTTCTGCCCTG 
TFEB forward: CAAGGCCAATGACCTGGAC 
TFEB reverse: AGCTCCCTGGACTTTTGCAG  
MCOLN1 forward: GAGTGGGTGCGACAAGTTTC 
MCOLN1 reverse: TGTTCTCTTCCCGGAATGTC  
WIPI forward: GCACAATCTCCCCTGAAGTC  
WIPI reverse: CCTCCTGGATATTCCTGCAA 
ATP6V0E1 forward: CATTGTGATGAGCGTGTTC  
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ATP6V0E1 reverse: AACTCCCCGGTTAGGACCCTTA 
4.5 Cell immunofluorescence 
1x105 Arpe19 cells were plated in 8-well Lab-Tek Chamber Slide (Nunc) or in 
Cell CarrierTM-96 plate (Perkin Elmer) for HCS analysis. 48h after plating, cells 
were fixed for 10 min in 4% PFA in PBS and then washed with PBS. For the 
detection of endogenous LC3, cells were fixed with cold methanol. 
Permeabilization and blocking was performed with 3% BSA-0.02% saponin in 
PBS (Blocking solution) for 1h. Cells were incubated with primary antibodies, 
diluted in blocking solution, over night at 4°C. The day after, cells were washed 
three times for 10 min with blocking solution and incubated for 1h with the 
secondary antibody (AlexaFluor-labelled) diluted 1:200 in blocking solution. 
For Shiga toxin staining, cells were incubated with 140 ng/ml Shiga (from J. 
Ludger) in blocking solution, together with secondary antibody, for 1h. After 
three washes of 10 min with blocking solution, slides were mounted with 
Vectashield mounting medium with dapi (Vector Laboratories) or, cells plated 
in 96-well-opera plates were incubated with DAPI for 5 min. Primary 
antibodies used for immunofluorescence experiments are: LAMP-1 (Santa 
Cruz, cat. sc-20011, 1:400), LC3 (Novus, cat. NB100-2220, 1:100). Shiga 
toxin-LAMP1 co-staining was detected by Zeiss LSM 880 Airyscan. Other 
confocal acquisitions were performed by Zeiss LSM 800. 
4.6 LysoTracker assay 
1x106 Arpe19 cells were collected and centrifuged at 1200 rpm for 5 min. Cell 
pellet was resuspended in 1ml PBS and incubated 5 min with LysoTracker Red 
DND-99 (Invitrogen) diluted 1:1000.  After two washes in PBS, followed by 
centrifugation as previously described, cells were resuspended in FACS 
solution (0.5% Trypsin – 5mM EDTA- 1% FBS in PBS) and fluorescence was 
analysed by Fluorescence-Activated Cell Sorting (FACS) using DB FACSAria. 
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4.7 High Content Screening and Electron Microscopy 
High Content Screening analysis were performed by D. Medina’s HCS facility 
at TIGEM. Opera system was used to acquire 15 fields for each sample at 40x 
magnification. Analysis of each field was performed by Columbus software 
(PerkinElmer) using the parameters listed in table 1. Electron Microscopy was 
performed by E. Polishchuk (Advanced Microscopy and Imaging facility, 
TIGEM). 
Table 1. Columbus analysis parameters 
 
4.8 Statistics 
GraphPad Prism (GraphPad Software, San Diego, CA) was used for all the 
statistical analysis. Statistical analyses of data were performed using Welch's t-
test. Unpaired t-test was applied to two independent groups, e.g. wt versus KO. 
This test compares the means of the two groups of data to determine whether 
the data have come from the same population or not. A p-value was calculated, 
where p is the probability of a false positive event. P-value <0.05 indicates that 
the false-positive rate is very low and was considered significant.
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5. Results 
5.1 Generation of GRN KO Arpe19 cell line by CRISPR-
Cas9 system 
5.1.1 In silico strategy design 
Bioinformatic analysis were performed in order to design two gRNAs targeting 
the coding sequence of GRN gene. The human GRN sequence is available on 
NCBI, Genbank NC_000017.11 (https://www.ncbi.nlm.nih.gov/nuccore/ 
NC_000017.11?report=genbank& from=44345086&to=44353106). The first 
step to identify suitable gRNAs was to check the presence of repetitive 
elements in the target region, in order to reduce the risk of off-target events. 
The exon 5 of GRN was scanned using the RepeatMasker software available on 
line (http://www.repeatmasker.org/cgi-bin/WEBRepeatMasker). Results 
reported in Fig.9 show that there are not repetitive elements in the input 
sequence. 
 
Fig.9 RepeatMasker output: the software scanned the input sequence (GRN exon 5) for 
repetitive elements. Output analysis shows that there are not repetitive elements in the selected 
sequence. 
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ZiFiT Targeter software was used to identify possible gRNAs in the GRN exon 
5 sequence (http://zifit.partners.org/ZiFiT/CSquare9Nuclease.aspx). With this 
program, it is possible to scan the input sequence for PAM motifs (NGG). The 
chosen setting parameters were: human genome and 20 nt as length of target 
site. The ZiFiT Targeter software allows the identification of off-targets 
indicating the numbers of mismatches for each off-target site. Two gRNAs 
were identified: the gRNA1 (CGAACTGACTATCAGGGCACCGG) 
recognizes three off-target sites, each of them with three mismatches, so 
reducing the risk of unwanted cleavages; the gRNA2 
(ACGTGCTGTGTTATGGTCGATGG) does not recognize off-target sites 
(Fig.10). 
 
Fig.10 gRNAs design and identification of off-target sites by ZiFiT Targeter software. Two 
gRNAs targeting the exon 5 of GRN were selected. The first gRNA (gRNA1) anneals with the 
plus strand of the target locus and is able to recognize three different off-target sites. The 
second gRNA (gRNA2) anneals with the minus strand and does not recognize off-target sites.   
5.1.2 In vivo application of CRISPR-Cas9 genome editing 
technology 
“All in one” strategy was chosen to efficiently achieve the genome editing of 
GRN. With this strategy it is possible to obtain one plasmid carrying both the 
human codon optimized wt Cas9 coding sequence, under the CMV promoter, 
and the gRNA sequence downstream the U6 promoter. gRNA sequence was 
cloned by Genecopoeia company into the pGS-CMV-Cas9/PURO vector 
containing puromycin resistence (Fig.11).  
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Arpe19 (retinal pigmented epithelium) cells were nucleofected with the vector 
carrying the Cas9 and the two gRNAs separately. After one week of selection 
with antibiotic, transfected cells were plated into 96 well plate in order to obtain 
single-cell derived colonies carrying the INDEL mutations. Single cell clones 
were duplicated into two different 96 well plates: one aimed to cell growth, the 
second one aimed to genomic DNA extraction, PCR amplification of the target 
locus and DNA Sanger sequencing in order to detect the INDEL mutations 
(Fig.11). Through Sanger sequencing only wt clones were detected using 
gRNA1, indicating that this guide was unable to drive the Cas9 to the target 
genomic site. By contrast, 50% of mutations were obtained with the gRNA2, 
30% of which carrying heterozygous mutations and 20% homozygous 
mutations (Fig.12A). Two GRN mutated clones were selected and 
characterized.  
The heterozygous clone sequencing displays a double peak starting from the 
Cas9 cleavage site. The homozygous clone presents 1bp (T/A) insertion in the 
gRNA target sequence, which generates a translational frameshift and a PTC, 
giving rise to a truncated PGRN protein, made of the half-granulin P and 
granulin G (Fig.12B).  
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Fig.11 CRISPR-Cas9 working flow chart: Arpe19 cells were transfected with the “all-in-one” 
vector containing the two gRNAs separately. Transfected cells were selected with puromycin 
and plated, by single cell sorting, into 96 well plate. The 96well plate of clones was duplicated 
to cell growth and to genomic DNA extraction, PCR amplification and sequencing. Cell clones 
carrying INDEL mutations were selected. 
 
Fig.12 CRISPR-Cas9 strategy results. (A) Percentage of Cas9 efficiency. Cas9 cleavage 
efficiency was 0% for gRNA1 and 50% for gRNA2. Among all the INDEL mutations (Mut) in 
the target site 2, 30% were heterozygous (Het) and 20% homozygous (Hom). (B) 
Electropherograms of two GRN mutated clones: the homozygous clone shows a T insertion (red 
rectangle) 3bp upstream the PAM sequence; the heterozygous clone presents a double peak 
electropherogram starting from 3bp upstream the PAM sequence (red arrow). gRNA2 sequence 
is highlighted with blue. 
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5.2 Validation of GRN+/- and GRN-/- Arpe19 cell lines 
GRN+/- and GRN-/- Arpe19 clones were validated by Real Time qPCR and 
Western blot (WB) analysis to detect GRN mRNA levels and PGRN protein 
expression levels. I revealed that PGRN protein expression is null in GRN-/- 
clone and half in GRN+/- clone compared to wt cells. As well as the real time 
analysis indicates that in GRN+/- clone GRN mRNA levels are half when 
compared to the wt, while in GRN-/- clone there is a four-fold reduction of the 
GRN mRNA amount (Fig.13A-B). 
 
Fig.13 Validation of GRN+/- and GRN-/- clones. (A) Western blot was performed to detect the 
PGRN levels in wild type (Wt), heterozygous (Het) and homozygous (Hom) cell lines. Results 
confirm a reduction in PGRN levels in GRN+/- and GRN-/- clones. Graph shows densitometry 
analysis of the Western blot bands. Values are normalized to actin and are shown as an average 
(** P ≤ 0.01, **** P ≤ 0.0001, Welch's t-test). (B) GRN transcriptional levels in Arpe19 
GRN+/+, GRN+/- and GRN-/- clones. Values are shown as an average (**** P ≤ 0.0001, Welch's 
t-test). 
5.3 Shiga toxin accumulation assay 
Storage of undigested material inside the lysosomes, in GRN+/- and GRN-/- cells, 
was checked using Shiga toxin accumulation assay. Shiga toxin is a toxin 
derived from Shigella dysenteriae 1 that interacts with 
Globotriaosylsphingosine (Gb3), a glycosphingolipid whose accumulation was 
demonstrated in other LSDs151. Immunofluorescence experiments were 
performed in order to follow Shiga toxin accumulation together with an 
antibody against the lysosomal marker Lysosomal-Associated Membrane 
Protein 1 (LAMP1). Co-staining of the red-fluorescent Shiga toxin and the 
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lysosomal marker LAMP1, displays a specific lysosomal storage of undegraded 
material only in GRN-/- cells (Fig.14). 
 
Fig.14 Gb3 accumulation in GRN+/+, GRN+/- and GRN-/- Arpe19 cells. Co-staining of Shiga 
toxin (red) and the lysosomal marker LAMP1 (green) shows a lipid accumulation, inside the 
lysosome, in GRN-/- cells. 
5.4 Analysis of lysosomal phenotype 
The amount of lysosomes in GRN+/- and GRN-/- Arpe19 cell lines was assayed 
by WB experiment using the antibody against LAMP1. These experiments 
revealed that in GRN-/- cells the amount of LAMP1 protein was considerably 
increased, while in GRN+/- cells, LAMP1 amount was comparable to wt cells 
(Fig.15A). Detection of lysosomes was also assayed by FACS experiments 
using the LysoTracker series of probes, which are weak bases attached to 
fluorophores. Weak bases are unprotonated at physiological pH so that they can 
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permeate cells and their organelles. Upon protonation in acidic environment, 
such as the lysosome, they become “trapped”152. FACS analysis was performed 
in both GRN-/-  and GRN+/- cells and obtained data confirmed  that in GRN+/- 
cell line the amount of lysosomes is normal, while in GRN-/- cells there is a 
considerable increase represented by the pick shift between wt and KO cells 
(Fig.15B). 
More important, LAMP1 immunostaining was also analyzed by HCS 
quantization. To this end, an “ad-hoc” script was designed to perform 
lysosomal morphometric analysis in the GRN-/- and GRN+/- Arpe19 cell lines. 
These results also confirmed the increased amount of lysosomes in absence of 
PGRN and revealed a lysosomal aggregation phenotype in the perinuclear 
region in GRN+/- but not in GRN-/- cells (Fig.16A-B).  
Lysosomal morphology was validated by Electron Microscopy (EM) 
experiments. Obtained EM images display bigger lysosomes in GRN-/- cells 
than in the wt ones (Fig.17A). Furthermore, in absence of PGRN, I observed a 
different lysosomal distribution. Indeed, in GRN-/- lysosomes are located closer 
to the plasma membrane than the lysosomes observed in wt cells (Fig.17B). 
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Fig.15 Detection of lysosomes amount. (A) Western blot showing LAMP1 protein levels in 
GRN+/- and GRN-/- cell lines. Wild type (Wt), heterozygous (Het), homozygous (Hom). Graph 
shows densitometry analysis of the Western blot bands. Values are normalized to actin and are 
shown as an average (**** P ≤ 0.0001, Welch's t-test). (B) FACS mediated detection of 
LysoTracker probes fluorescence. Pick shift between wt and GRN KO cells represents the 
increased amount of lysosomes. 
 
Fig.16 Lysosomes amount and aggregation. (A) LAMP1 immunostaining (green) reveals an 
increased number of lysosomes in GRN-/- cells and a perinuclear distribution of lysosomes in 
GRN+/- cells. (B) HCS analysis confirms the higher number of lysosomes per cell in absence of 
PGRN (upper graph) and evinces an aggregation of lysosomes in heterozygous condition (lower 
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graph). Wild type (Wt), heterozygous (Het), homozygous (Hom). Upper graph reports the 
number of LAMP1 spots per cell, lower graph shows the percentage of cells with LAMP1 
aggregation. Values are shown as an average (* P ≤ 0.05, **** P ≤ 0.0001, Welch's t-test). 
 
Fig.17 Lysosomal morphology and positioning. (A) Electron microscopy images of GRN+/+ and 
GRN-/- cells. GRN-/- cells show bigger lysosomes with respect to cells with normal PGRN 
levels. (B) HCS analysis showing an increased number of lysosomes located to the plasma 
membrane (PM) in absence of PGRN. Wild type (Wt), heterozygous (Het), homozygous 
(Hom). Values are normalized to the number of LAMP1 spots per area and are shown as an 
average (* P ≤ 0.05, Welch's t-test). 
5.5 Analysis of autophagic phenotype 
Immunostaining of the autophagosome marker microtubule-associated protein 
1A/1B-light chain 3 (LC3) in GRN+/+, GRN+/- and GRN-/- cells revealed a higher 
number of autophagosomes in absence of PGRN (Fig.18A). This result was 
confirmed by HCS quantization of LC3 spots per cell (Fig.18B). 
LC3 protein, when located on the autophagosome membrane, is lipidated and 
called LC3II. GRN+/+, GRN+/- and GRN-/- cells were starved 1h with HBSS 
(inducing the autophagic flux) or treated for 1h with Bafilomycin A1 (BafA1), 
a specific inhibitor of the vacuolar type H+-ATPase (V-ATPase) located to the 
lysosomes. BafA1 inhibits the acidification of organelles and subsequent 
autophogosomes-lysosomes fusion153. Detection of LC3II by WB revealed that 
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GRN-/- cells show a higher number of autophagosomes than the wt cells when 
starved or treated with BafA1. In GRN+/- cells, instead, there is a reduction of 
the autophagosomes amount in both conditions compared to GRN+/+ cells 
(Fig.19). 
In order to analyse the levels of autophagosome-lysosome fusion, GRN+/+, 
GRN+/- and GRN-/- cells were transfected with a plasmid expressing LC3 protein 
fused to the Green Fluorescent Protein (GFP) and the Red Fluorescent Protein 
(RFP). GFP is a stably folded protein resistant to lysosomal proteases, but the 
low pH inside lysosomes quenches its fluorescent signal. In contrast, RFP 
exhibits a more stable fluorescence in acidic compartments allowing the 
detection of the red signal into the autolysosomes121. Transfected cells were not 
treated and treated with HBSS or Bafilomycin A1 as positive (induction of 
autophagy and increased autophagosomes-lysosome fusion) and negative 
(block of autophagosomes-lysosome fusion) controls respectively. Results 
reported in Fig.20 underline a reduced autolysosomes formation in GRN+/- cells 
and a block of autophagosomes-lysosomes fusion in GRN-/- cells with respect to 
wt cells.  
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Fig.18 Amount of autophagosomes related to PGRN dosage. (A) Immunostaining of LC3 
(green) showing an increased number of LC3 spots in GRN KO cells. (B) HCS analysis 
reporting the number of LC3 spots/cell. Wild type (Wt), heterozygous (Het), homozygous 
(Hom).  Values are shown as an average (*** P ≤ 0.001, Welch's t-test). 
 
Fig.19 Analysis of autophagic induction. GRN+/+, GRN+/- and GRN-/- cells were treated with 
HBSS (nutrient privation) or 100 nM Bafilomycin A1 (BafA1) for 1h. Western blot assay of 
LC3II protein shows reduced autophagosomes formation in GRN+/- cells and an increased 
autophagosomes amount in GRN-/- cells with respect to wt cells, after starvaion and BafA1 
treatment. Wild type (Wt), heterozygous (Het), homozygous (Hom). Graph shows densitometry 
analysis of the Western blot bands. Values are normalized to actin and are shown as an average 
(*** P ≤ 0.001, **** P ≤ 0.0001, Welch's t-test). 
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Fig.20 Autophagosomes-lysosomes fusion assay. GRN+/+, GRN+/- and GRN-/- cells transfected 
with LC3-RFP-GFP were not treated (fed) and treated with HBSS (stv) or 100 nM Bafilomycin 
A1 (baf) for 1h. Yellow dots are representative of autophagosomes, red dots of autolysosomes. 
Graph reports the percentage of red dots per cell. Wild type (Wt), heterozygous (Het), 
homozygous (Hom). Values are normalized to number of total spots per cell and are shown as 
an average (* P ≤ 0.05, ** P ≤ 0.01, **** P ≤ 0.0001, Welch's t-test). 
5.6 mTORC1 signalling 
mTORC1 activity in GRN edited cells was assayed by WB experiments in 
which the phosphorylation levels of its targets were detected. Eukaryotic 
translation initiation factor 4E-Binding Protein 1 (4EBP1) and TFEB are 
mTORC1 kinase substrates, which modulate their activity through translational 
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modifications. WB results show a decreased 4EBP1 and TFEB phosphorylation 
in GRN+/- and GRN-/- cells when compared to wt cells. Moreover, GRN 
heterozygous and homozygous clones showed an increased level of TFEB 
protein (Fig.21).  
Once dephosphorylated, TFEB migrates into the nucleus where it activates the 
transcription of its targets. To test the transcriptional activation of TFEB 
targets, a Real Time qPCR was performed on cDNAs derived from mRNAs of 
GRN+/+, GRN+/- and GRN-/- cells. Results reported in Fig.22 display higher 
transcriptional levels of TFEB itself and of its targets (MCOLN1, WIPI and 
ATP6VoE1) in GRN heterozygous and homozygous conditions, confirming a 
lower level of phosporylated TFEB and its subsequent traslocation into the 
nucleus. 
 
Fig.21 PGRN dependent mTORC1 activity. GRN+/+, GRN+/- and GRN-/- cells were not treated 
(fed) and treated with 1h HBSS (stv) as negative control. In absence of nutrients mTORC1 is 
inactive and does not phosphorylates its targets. Western blot analysis shows a decreased 
phosphorylation of 4EBP1 and TFEB in GRN+/- and GRN-/- cell lines with respect to wt cells. 
Wild type (Wt), heterozygous (Het), homozygous (Hom). Graph shows densitometry analysis 
of the Western blot bands. Values are normalized to actin and are shown as an average (**** P 
≤ 0.0001, Welch's t-test). 
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Fig.22 TFEB targets relative mRNA levels. Real time qPCR of TFEB targets (TFEB, 
MCOLN1, WIPI and ATP6V0E1) in GRN+/+ (Wt), GRN+/- (Het) and GRN-/- (Hom) cells 
revealed that in GRN edited cells there is an enhanced transcriptional activation of TFEB targets 
with respect to wt cells. Values reported in graph are shown as an average (* P ≤ 0.05, ** P ≤ 
0.01, *** P ≤ 0.001, **** P ≤ 0.0001, Welch's t-test). 
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6. Discussion 
NCL11 is an autosomal recessive adulthood neurodegenative disease caused 
by homozygous null mutations in GRN gene94 and characterized by the 
lysosomal accumulation of autofluorescent material15,16,109. Recent reports 
show that GRN deficiency leads to lysosomal dysfunction through 
accumulation of abnormal autofluorescent lipopigments72,114, even though,  the 
mechanism by which this protein acts at the lysosomes, and how its dysfunction 
leads to NCL11 diseases, is still not known. This lack of knowledge makes it 
difficult to apply any good therapy to ameliorate patient condition and to stop 
disease progression.  
The starting point to study protein functions and dysfunction in pathological 
conditions, is to generate a good model system resembling the disease of 
interest. Currently, in order to investigate the role of GRN, different NCL11 
model systems, like GRN deficient mice72,76,112,154,155 and primary cultures of 
GRN KO mice derived cells72,73, have been generated. Thanks to these models, 
many of the GRN functions have been clarified, but its role in regulating 
lysosomal metabolism is still not clear and a good therapy for NCL11 is far to 
be applied. One of the main features of all the models available to study 
NCL11, is the high level of variability,  that makes them not suitable candidates 
for experiments of drugs discoveries by HCS, which require an highly 
homogeneous cell population. For this reason, the main purpose of this work 
was to generate a new NCL11 cellular model able to reproduce the disease 
phenotype and suitable for both cell biology and biochemical approaches, in 
order to clarify the specific role of GNR within lysosomes, and to perform HCS 
experiments, such as drugs discovery.     
Few years ago a new efficient technology of genome editing, the CRISPR-Cas9 
system, emerged from the engineering of S. pyogenes immunity system. 
Through this approach, I was able to edit GRN gene in Arpe19 cells. This cell 
line was chosen because retinal dystrophy and retina lipofuscin accumulation 
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occur in NCL11 patients and mice models109,110,156. Obtained GRN KO cells 
displayed lipids storage in the lysosomes, validating this cellular system as a 
suitable in vitro model for NCL11. Instead, lipids accumulation, as expected, 
was not observed in GRN+/- cell line, since GRN heterozygous null mutations 
lead to a non-lysosomal storage disease. Furthermore, despite lipofuscin 
autofluorescent lipopigments were detected in retina of GRN-/- mice157, they 
were impossible to be observed in GRN KO cells, probably due to cellular 
division related-dilution.  
The concept of LSDs as “autophagy disorders” has emerged in the last years158 
since lysosomes play a key role in the autophagic pathway, by fusing with 
autophagosomes and digesting their content. Considering the highly integrated 
function of lysosomes and autophagosomes, it was reasonable to expect that 
lysosomal storage in LSDs would have an impact upon autophagy 115-117. In 
fact, an accelerated storage of the ubiquitinated proteins and of the aging 
pigment lipofuscin, that normally accumulates in brain during aging, in NCL11 
mice models72,112,114,159, suggests an impairment in the autophagic-lysosomal 
degradation machinery. Therefore, I investigated the effect of GRN 
haploinsufficiency and depletion on the autophagic pathway in my cellular 
models. By different approaches, I revealed a higher number of 
autophagosomes in GRN-/- Arpe19 cells than in wt cells. Since the 
autophagosome is an intermediate structure in a dynamic process, the simple 
mesurement of the numbers of autophagosomes was not sufficient for a general 
estimation of the autophagic activity121. For this reason, I performed 
experiments of modulation of the autophagic flux to evaluate the autophagic 
levels, revealing an increase in GRN-/- and a reduction in GRN+/- conditions. 
Wils H. et al. observed, in brain of GRN-/- mice, more p62-positive inclusions 
than wt mice112. p62 is an autophagosome related protein, which binds LC3 
protein on one side, and the ubiquitinated cargo, that must be degraded, on the 
other side. Once the fusion between autophagosomes and lysosomes occurs, 
p62 protein is degraded by lysosomal proteases together with the cargo160. 
Increase of p62 inclusions in GRN-/- mice brain suggests a damage in 
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autophagosome-lysosome fusion. The NCL11 cellular model system that I 
generated confirmed the autophagosome-lysosome fusion impairment and this 
finding, together with the enhanced autophagic activity, explains the increase in 
the number of autophagosomes in GRN KO cells.  
Another important observation was the different cellular phenotypes in GRN 
haploinsufficiency and KO conditions. In fact, through immunofluorescence 
experiments and a specific script designed to perform HCS quantification, I 
revealed a higher number of lysosomes in GRN-/- cells than GRN+/- and wt cells. 
Moreover, to further demonstrate the potency of this tool as a good candidate 
for HCS and drug discovery experiments, a quantification of the lysosomal 
distribution was performed in these cell lines. Obtained results revealed that, 
while Arpe19 wt cells display a uniform lysosomal distribution into the cytosol, 
GRN+/- cells present a lysosomal perinuclear aggregation, and, in contrast, 
GRN-/- cells show a higher number of lysosomes located to the plasma 
membrane. Electron Microscopy experiments indicate that lysosomes show a 
bigger size in GRN-/- cells than in wt. Furthermore, I evinced an impaired 
lysosomal trafficking in GRN edited cells (data not shown), confirming a direct 
or indirect role of PGRN (or related-granulins) in lysosome movement, 
localization and subsequent function.  
An important player in the regulation of the autophagic process and lysosomal 
metabolism is the nutrient-responsive kinase mTOR.  Defects in the 
autophagic-lysosomal pathway, due to abnormal mTORC1 activation, are 
reported in several LSDs124. Tanaka Y. et al. demonstrated an impairment in 
mTORC1 activity in cerebral cortex of PGRN-deficient mice161. Thus, a slight 
reduction of the kinase complex activity in GRN+/- cells and a remarkable 
inactivation in GRN-/- cells, further confirmed the potency of GRN-/- Arpe19 cell 
line as a good in vitro model system for NCL11. Phosphorylation/ 
dephosphorylation status of the mTORC1 substrate, TFEB, is an important 
regulatory mechanism for its activation. Since I found that in GRN-/- and GRN+/- 
cells the levels of TFEB phosphorilation were less than in wt cells, to confirm 
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the activation status of TFEB, I performed real time PCR experiments to 
analyze the expression levels of TFEB target genes. As expected, I found 
enhanced transcriptional levels of some TFEB target genes, confirming that in 
these cell lines TFEB is constitutively activated.   
It has been demonstated that secreted PGRN interacts with the membrane 
receptor Sortilin, inducing endocytosis and transport of PGRN to the 
lysosome92. Tanaka Y. et al. suggested that the lysosomal localization of PGRN 
is related to its possible involvement in mTORC1 activation and subsequent 
cytosolic TFEB retention161. Through my GRN KO cell model system I could 
confirm the role of GRN in regulating mTORC1 activity.  Moreover, Sardiello 
M. et al. demonstrated that in cells derived from LSDs mice there is a 
predominant nuclear localization of TFEB, suggesting that, after intralysosomal 
storage of undegraded material, TFEB pathway is activated as a cellular 
response to enhance cellular clearance124. This model is reproduced in GRN KO 
cells, even if it is evident that the enhanced autophagic-lysosomal pathway 
alone is not able to lead cell clearance. The persistency of the cell phenotype 
could be due to the fusion defect between autophagosome and lysosomes that 
makes the “clearance” strategy adopted by the cell uneffective.  Strikingly, 
GRN by itself is a target gene of the active TFEB, thus underlining a main role 
of PGRN in lysosomal function. 
In conclusion, by this work I generated a new and reliable model system for 
NCL11 through the innovative technology of genome editing, the CRISPR-
Cas9 system. I obtained and characterized the GRN+/- and GRN-/- Arpe19 cell 
lines, highlighting the damaged lysosomal and autophagic pathways and 
pointing out the attention on the different phenotypes related to PGRN dosage, 
which reflects the onset of two independent diseases in cases of heterozygous or 
homozygous null mutations in GRN gene. These cellular models are good 
candidates for experiments of HCS thanks to the abolition of variability that 
occurs using primary cell cultures. Thus, these cell lines allow experiments of 
drug screening aimed to the detection of new compounds able to revert the 
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disease phenotype and that could lead to the development of a suitable and 
reliable therapy to stop the disease progression. 
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